Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Lilly Alzheimer's drug not to be covered by U.K.'s NHS
Eli Lilly Alzheimer’s Drug Rejected for NHS Use in England
Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.
Lilly's Alzheimer's drug approved in the UK
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the company said on Wednesday.
NHS to Block Eli Lilly's Alzheimer's Drug Donanemab Over Cost Concerns: Report
The National Institute for Health and Care Excellence (NICE), which decides what drugs are available on the NHS, will rule that it is too expensive
NHS will not fund new drug to slow Alzheimer’s
A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the watchdog says.
Lilly Alzheimer's drug not to be covered by U.K.'s NHS: report
U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early Alzheimer’s disease because it’s too expensive. Read more here.
UK's NHS to block Eli Lilly's Alzheimer's drug on Wednesday, Telegraph reports
Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too expensive for NHS patients, the Telegraph reported on Tuesday. British regulators are expected to declare the drug safe for use on Wednesday,
Alzheimer’s wonder drug faces NHS block over cost
The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare the new treatment for the disease safe for use but the rationing body for the health service will immediately rule that it is too expensive for NHS patients.
47m
on MSN
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
And it looks like Johnson & Johnson (NYSE: JNJ) just hit a bump in the road that'll pave the way for Eli Lilly (NYSE: LLY) to ...
12h
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors despite daily gains
Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.
1d
on MSN
Eli Lilly sues over knockoffs of signature weight loss drug, Zepbound
Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its ...
STAT
1d
Senators demand answers on telehealth platforms from Pfizer and Eli Lilly
Led by Sen. Dick Durbin of Illinois, senators question if direct-to-consumer website telehealth deals are a new way around ...
6d
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
1d
Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug
Eli Lilly sues vendors for selling unauthorized tirzepatide amid resolved shortages. Lawsuits target vendors offering ...
7d
How Eli Lilly Outpaces Nvidia—Here Is One Chart
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
1d
Mangoceuticals ‘refutes’ claims by Eli Lilly regarding sale of tirzepatide
Mangoceuticals (MGRX) learned earlier this morning that Eli Lilly (LLY) has made certain public claims alleging, and has stated that it ...
STAT
19h
Pharmalittle: We’re reading about a probe of Pfizer and Lilly telehealth, pharma exec donations, and more
Dick Durbin (D-Ill.) demanded answers from Pfizer and Eli Lilly about their relationships with the telehealth prescribers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Zepbound
New York Stock Exchange
United States
Food and Drug Administration
Pfizer
Feedback